Johnson & Johnson (JNJ) investment Quality Rating (A)

(A) | Healthcare | Pharmaceuticals
By: Old York Financial
A Private Principal Research Report

the verdict

Old York Financial has assigned Johnson & Johnson (JNJ) an Operational Quality (A) Rating. Following the Kenvue spin-off, JNJ has re-emerged as a "Pure-Play Healthcare Sovereign," shedding its slow-growth consumer skin to focus on high-margin BioPharma and MedTech. 2025 was a "Velocity Year," with revenue hitting $94.2 Billion (up 6%) and Adjusted Net Earnings reaching $26.2 Billion. It earns an (A) because it remains the most diversified healthcare fortress on earth, but stays below (AA) due to the "Talcum overhang" a litigation vortex with 67,000+ pending cases and recent jury verdicts exceeding $1.5 Billion. For the Principal, JNJ is the "Lindy Effect" personified: a 140-year-old machine that remains one of the world's only AAA-rated credit (S&P), even if its operational rating is tempered by legal friction.

the old york analysis

owner earnings: the post-consumer surplus In the JNJ model, we audit the cash production of the new, leaner architecture.

• 2025 Net Cash from Operations: $24.5 Billion

• (-) Capital Expenditures (2025): ($4.8 Billion)

• (+) Depreciation & Amortization: $7.2 Billion

• OLD YORK OWNER EARNINGS: $26.9 Billion

Analyst Note: JNJ is a "Cash Compounding Sovereign." With Owner Earnings essentially matching Adjusted Net Income, the quality of the profit is high. The company converts nearly 29% of every revenue dollar into raw cash power before dividends. This is the "Fuel" that funds their $15B+ annual R&D engine.

growth & market dominance

• Total Revenue (2025): $94.2 Billion (Up 6.0%).

• Innovative Medicine (BioPharma): $60.4 Billion (Up 6%). Driven by the Darzalex monopoly in multiple myeloma and the resilience of Erleada.

• MedTech: $33.8 Billion (Up 6%). Accelerated by the $13B Shockwave Medical acquisition, making JNJ a "Category King" in cardiovascular intervention.

• Pricing Power: SYSTEMIC. JNJ doesn't just sell drugs; it sells "Standard of Care." With 13 brands generating $1B+ annually, they possess an "Anti-Fragile" portfolio where the loss of exclusivity on Stelara (~$10B) is being methodically absorbed by a pipeline of 10+ potential $5B blockbusters.

• Moats: The "Institutional Lock-in." JNJ is embedded in every hospital's procurement system. Their MedTech moat is physical (robotic surgery/stents), and their BioPharma moat is clinical.

operational efficiency

• 5-Year ROIC (Avg): 17.48%

• 5-Year EPS CAGR: 26.45%

• 5-Year Price CAGR: 8.55%

• Share Change (5Y): -8.54%

• Analyst Note: Since the Kenvue spin, JNJ's margins have sharpened. They are no longer managing Band-Aids and Tylenol; they are managing high-IP oncology and robotic hearts. The efficiency of the machine has improved by 400 basis points since 2023.

the fortress check

• Total Debt: $39.4 Billion.

• Cash & Equivalents: $19.7 Billion.

• Dividend Payout Ratio: 48% (63 consecutive years of increases).

• Capital Allocation: AGGRESSIVE M&A. In 2025 alone, JNJ deployed over $32 Billion into R&D and acquisitions (Shockwave, Halda, etc.).

• The "Litigation" Gear: The talc litigation is the only "Sand in the Gears." While JNJ has $19B in cash, the Baltimore $1.5B verdict and the collapse of the "Texas Two-Step" bankruptcy strategy mean the Principal must set aside massive reserves for a final global settlement.

• Solvency: ABSOLUTE. JNJ is one of only two US companies with a triple-A credit rating from S&P. Their balance sheet is stronger than the US Treasury in some cycles.

final determination

Rating: Old York Quality (A)

Classification: The Global Healthcare Sovereign.

Johnson & Johnson is the "Final Boss" of the healthcare sector. It receives an (A) because its core business is a (AAA), but its legal liabilities are a (B). The result is a rock-solid (A). For a principal, JNJ is the ultimate "Core Holding" that provides a 3%+ yield while building the future of surgery.

Disclaimer: Old York Financial operates privately as a principal and sells corporate advisory. Old York Financial is not an accountant, a financial advisor, a broker, an agent, a lawyer, or a portfolio manager. This report is for informational purposes only.